奥沙利铂联合卡培他滨治疗晚期大肠癌35例  

Efficacy of Oxaliplatin combined with Capecitabine therapy for advanced colorectal cancer

作　　者：刘晓青[1] 董柱清[1] 吴传高[1] 

机构地区：[1]福建医科大学附属闽东医院放疗科,福建福安355000

出　　处：《中国现代医生》2012年第10期129-130,132,共3页China Modern Doctor

摘　　要：目的观察奥沙利铂联合卡培他滨治疗晚期大肠癌的临床疗效及毒副反应。方法我院2008年1月～2009年6月共收治35例晚期大肠癌患者,均采用奥沙利铂联合卡培他滨治疗,具体为:奥沙利铂130 mg/m2,ivgtt 2h,d1;卡培他滨1250 mg/m2,po,bid,d1～14,21d为1个周期。结果 35例患者均可进行疗效评价,CR 3例(8.6%),PR 17例(48.6%),SD 13例(37.1%),PD 2例(5.7%),总有效率(CR+PR)为57.2%,中位OS 19.2个月,中位PFS 8.1个月。主要的毒副反应为消化道反应、血液毒性、神经毒性、手足综合征等,经对症处理后患者均能耐受。结论奥沙利铂联合卡培他滨治疗晚期大肠癌疗效显著,毒副反应小,耐受性好,是值得临床推广应用的姑息化疗方案。Objective To observe the efficacy and toxicity of oxaliplatin combined capecitabine therapy for advanced colorectal cancer. Methods All of 35 advanced eolorectal cancer patients were treated by oxaliplatin combined capeeitabine, Oxaliplatin injection of 130 mg/m2 was given to the patients on the first day, and capecitabine per os of 1 250 mg/m2 twice a day was given to the patients from 1st to 14th days, 21 days for a cycle. Results All of 35 cases were evaluable for efficacy. There were 3 complete response（CR）, 17 patial response（PR）, 13 stable disease（SD） and 2 progress dlsease（PD）. The total efficacy was 57.2%, median overall survival（OS） was 19.2 months, and median progression-free survival（PFS） was 8.1 months. The most common toxicities were gastrointestinal reactions, blood toxicity, neurotoxicity, hand-foot syndrome, but all of them could be tolerable after appropriate treatment. Conclusion Oxaliplatin combined with capecitabine was an effective and well tolerated palliative chemotherapy regimen in the treatment of advanced eolorectal cancer and the toxicity was small. It was worth of further clinical research.

关 键 词：奥沙利铂 卡培他滨 毒副反应 晚期大肠癌 

分 类 号：R735.3[医药卫生—肿瘤]